Aclaris Therapeutics Statistics
Total Valuation
ACRS has a market cap or net worth of $921.47 million. The enterprise value is $752.69 million.
| Market Cap | 921.47M |
| Enterprise Value | 752.69M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRS has 147.20 million shares outstanding. The number of shares has increased by 25.53% in one year.
| Current Share Class | 147.20M |
| Shares Outstanding | 147.20M |
| Shares Change (YoY) | +25.53% |
| Shares Change (QoQ) | +10.81% |
| Owned by Insiders (%) | 2.21% |
| Owned by Institutions (%) | 58.44% |
| Float | 109.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 113.01 |
| Forward PS | 177.92 |
| PB Ratio | 7.08 |
| P/TBV Ratio | 7.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 92.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.46, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.46 |
| Quick Ratio | 3.46 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -59.10% and return on invested capital (ROIC) is -41.03%.
| Return on Equity (ROE) | -59.10% |
| Return on Assets (ROA) | -28.98% |
| Return on Invested Capital (ROIC) | -41.03% |
| Return on Capital Employed (ROCE) | -56.46% |
| Weighted Average Cost of Capital (WACC) | 8.54% |
| Revenue Per Employee | $112,589 |
| Profits Per Employee | -$1.04M |
| Employee Count | 73 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +250.56% in the last 52 weeks. The beta is 0.78, so ACRS's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | +250.56% |
| 50-Day Moving Average | 5.48 |
| 200-Day Moving Average | 4.04 |
| Relative Strength Index (RSI) | 61.65 |
| Average Volume (20 Days) | 1,864,647 |
Short Selling Information
The latest short interest is 13.77 million, so 9.36% of the outstanding shares have been sold short.
| Short Interest | 13.77M |
| Short Previous Month | 13.36M |
| Short % of Shares Out | 9.36% |
| Short % of Float | 12.53% |
| Short Ratio (days to cover) | 7.52 |
Income Statement
In the last 12 months, ACRS had revenue of $8.22 million and -$75.74 million in losses. Loss per share was -$0.59.
| Revenue | 8.22M |
| Gross Profit | -62.28M |
| Operating Income | -85.51M |
| Pretax Income | -75.74M |
| Net Income | -75.74M |
| EBITDA | -85.53M |
| EBIT | -85.51M |
| Loss Per Share | -$0.59 |
Balance Sheet
The company has $91.56 million in cash and $1.85 million in debt, with a net cash position of $168.77 million or $1.15 per share.
| Cash & Cash Equivalents | 91.56M |
| Total Debt | 1.85M |
| Net Cash | 168.77M |
| Net Cash Per Share | $1.15 |
| Equity (Book Value) | 124.58M |
| Book Value Per Share | 0.89 |
| Working Capital | 69.52M |
Cash Flow
In the last 12 months, operating cash flow was -$62.06 million and capital expenditures -$118,000, giving a free cash flow of -$62.18 million.
| Operating Cash Flow | -62.06M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | -12,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -62.18M |
| FCF Per Share | -$0.42 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,040.43% |
| Pretax Margin | -921.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.53% |
| Shareholder Yield | -25.53% |
| Earnings Yield | -8.15% |
| FCF Yield | -6.69% |
Analyst Forecast
The average price target for ACRS is $10.20, which is 62.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.20 |
| Price Target Difference | 62.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | -10.02% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ACRS has an Altman Z-Score of -4.91 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.91 |
| Piotroski F-Score | 1 |